Skip to main content

Table 2 Core and surrogate Maternal and Neonatal Tetanus Elimination (MNTE) sustainability indicators, platforms for introducing Tetanus Toxoid-Containing Vaccines (TTCV) booster doses, and Gavi eligibility status in the 28 countries that were validated for MNTE elimination during 2011–2020

From: Sustaining Maternal and Neonatal Tetanus Elimination (MNTE) in countries that have been validated for elimination – progress and challenges

Country

Year validated for MNTE

 

MNTE sustainability indicators

TTCV booster dose in national vaccination schedules

TTCV booster platforms

Gavi support [16]

DTP3 [11]

TTCV2 + [11]

PAB [12]

ANC1 [13, 14]

ANC4 [13, 14]

HFD [13, 14]

SBA [13, 14]

1st booster [11]

2nd booster, [11]

3rd booster [11]

SVP exists [11]

MCV2 Intro [11]

HPV Intro [11]

 

Burkina Faso

2012

91%

69%

95%

ND

ND

ND

ND

No

No

No

No

Yes

No

Yes

Cambodia

2015

92%

77%

95%

95%

79%

83%

89%

No

No

No

No

Yes

No

Yes

Cameroon

2012

69%

62%

83%

87%

65%

65%

69%

No

No

No

No

No

No

Yes

Chad

2019

52%

74%

78%

ND

ND

ND

ND

No

No

No

No

No

No

Yes

China

2012

99%

ND

ND

ND

ND

ND

ND

Yes

Yes

No

No

Yes

No

No

Cote d'Ivoire

2013

80%

75%

86%

ND

ND

ND

ND

No

No

No

Yes

No

Yes

Yes

DRC

2019

57%

96%

85%

ND

ND

ND

ND

No

No

No

No

No

No

Yes

E/Guinea

2015

53%

36%

60%

ND

ND

ND

ND

No

No

No

No

No

No

No

Ethiopia

2017

71%

90%

90%

74%

43%

48%

50%

No

No

No

Yes

Yes

Yes

Yes

Gabon

2013

63%

43%

83%

ND

ND

ND

ND

No

No

No

No

No

No

No

Ghana

2011

94%

62%

90%

98%

89%

79%

79%

No

No

No

No

Yes

No

Yes

G/Bissau

2012

74%

44%

83%

ND

ND

ND

ND

No

No

No

No

No

No

Yes

Haiti

2016

51%

44%

80%

91%

67%

39%

42%

Yes

No

No

No

Yes

No

Yes

India

2015

91%

78%

90%

79%

51%

79%

81%

Yes

Yes

No

No

Yes

No

Yes

Indonesia

2016

77%

54%

85%

98%

77%

74%

91%

Yes

Yes

Yes

Yes

Yes

Yes

No

Iraq

2013

74%

42%

73%

ND

ND

ND

ND

Yes

Yes

No

No

Yes

No

No

Kenya

2018

89%

ND

88%

ND

ND

ND

ND

No

No

No

No

Yes

Yes

Yes

Lao PDR

2013

79%

43%

93%

ND

ND

ND

ND

No

No

No

No

Yes

No

Yes

Liberia

2011

65%

20%

90%

98%

87%

80%

84%

No

No

No

No

Yes

Yes

Yes

Madagascar

2014

68%

52%

75%

ND

ND

ND

ND

No

No

No

No

No

No

Yes

Mauritania

2015

71%

31%

83%

85%

38%

70%

72%

No

No

No

No

No

No

Yes

Niger

2016

81%

71%

83%

ND

ND

ND

ND

No

No

No

No

Yes

No

Yes

Philippines

2015

71%

39%

91%

94%

87%

78%

84%

No

No

No

Yes

Yes

No

No

Senegal

2011

91%

68%

95%

98%

56%

80%

74%

No

No

No

Yes

Yes

Yes

Yes

Sierra Leone

2013

91%

95%

93%

98%

79%

83%

87%

No

No

No

No

Yes

No

Yes

Tanzania

2012

86%

100%

91%

98%

51%

63%

64%

No

No

No

Yes

Yes

Yes

Yes

Timor–Leste

2012

86%

34%

83%

84%

77%

49%

57%

Yes

Yes

No

Yes

Yes

No

Yes

Uganda

2011

89%

65%

83%

97%

60%

73%

74%

No

No

No

Yes

No

Yes

Yes

  1. E/Guinea Equatorial Guinea, G/Bissau Guinea Bissau, Lao PDR Lao People’s Democratic Republic, MNTE maternal and neonatal tetanus elimination, TTCV tetanus toxoid containing-vaccines, TTCV2 + at least two doses of tetanus toxoid containing-vaccines, DTP3 third dose of diphtheria-tetanus-pertussis vaccine, PAB protection at birth against tetanus, ANC1 one antenatal care visit, ANC4 four antenatal care visits, HFD health facility delivery, SBA skilled birth attendance, SVP school vaccination program, MCV2 intro introduction of second dose of measles containing vaccines, HPV intro introduction of human papillomavirus vaccine, Gavi Gavi, the Vaccine Alliance ND No data